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Abstract: Several health benefits, associated with human milk oligosaccharides (HMOS), have been
revealed in the last decades. Further progress, however, requires not only the establishment of a simple
“routine” method for absolute quantification of complex HMOS mixtures but also the development of
novel synthesis strategies to improve access to tailored HMOS. Here, we introduce a combination
of salvage-like nucleotide sugar-producing enzyme cascades with Leloir-glycosyltransferases in a
sequential pattern for the convenient tailoring of stable isotope-labeled HMOS. We demonstrate
the assembly of [13C6]galactose into lacto-N- and lacto-N-neo-type HMOS structures up to octaoses.
Further, we present the enzymatic production of UDP-[15N]GlcNAc and its application for the
enzymatic synthesis of [13C6/15N]lacto-N-neo-tetraose for the first time. An exemplary application was
selected—analysis of tetraose in complex biological mixtures—to show the potential of tailored stable
isotope reference standards for the mass spectrometry-based quantification, using matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) as a fast and straightforward
method for absolute quantification of HMOS. Together with the newly available well-defined tailored
isotopic HMOS, this can make a crucial contribution to prospective research aiming for a more
profound understanding of HMOS structure-function relations.
Keywords: glycobiology; biocatalysis; human milk oligosaccharides; isotopic labeling; quantification:
nucleotide sugars; lacto-N-biose type; lacto-N-neo type; glycosyltransferases; capillary gel
electrophoresis; MALDI-MS
1. Introduction
It has become increasingly apparent that human milk oligosaccharides (HMOS) consist of a cocktail
of complex glycans and play important biological roles well beyond simple nutrition. Most of HMOS
are involved in very complex and important biological mechanisms [1,2], protecting the gastrointestinal
tract against toxin and viral and bacterial adhesion, mediating immune modulations and stimulating the
brain development and several more [1–3]. HMOS are present in large quantities and are the third most
abundant group of compounds in human milk, directly after lactose and lipids [3–5]. They display a unique
and extremely high structural diversity [2,3,6,7], with approximately 150 elucidated structures so far [8].
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Interestingly, it has been found that biological functions depend on both, the specific structure
and the quantity of the HMOS present [8,9]. Striking is also their remarkable variability in composition
and concentration of milk oligosaccharides (milk OS) during lactation depending on the donor
phenotype [10]. Therefore, methods for absolute quantification of milk OS are of high interest and a
prerequisite for the deeper understanding of the biological roles of HMOS. Moreover, a rising amount
of HMOS is authorized as a nutrition supplement, which promotes an urgent future request for a rapid
and robust “routine” quantification method for suitable quality control [11–13].
However, absolute quantification of milk OS has been proven to be a challenging task. The most
commonly applied chromatographic, electrophoretic, and spectrometric methods often deliver
only relative quantification of milk OS [14–16]. One reason for limited attempts to quantify
diverse and complex milk OS is a small number of available standards. Matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) methods combined with
stable isotope labeling have already been successfully applied for absolute quantification of other
complex OS like N-glycans [17]. Nevertheless, this technique also relies on the availability of
isotope-labeled internal standards [17–19]. Improved access to tailored isotopically labeled milk OS
would enable the application of fast and straightforward MALDI-TOF-MS-based methods for absolute
quantification of milk OS, suitable also for a complex sample matrix-like human milk.
Beside chemical routes for the HMOS synthesis [20,21], the enzyme-mediated HMOS tailoring
is a very straightforward strategy [7,21–25]. Leloir-glycosyltransferases are especially known
for their quantitative substrate conversion, a very high specificity, and high regioselectivity
by utilizing activated nucleotide sugars [26]. Availability of recombinant enzymatic tools
like a β1,4-galactosyltransferase-1 (β4GalT) [27,28], a β1,3-N-acetylglucosaminyltransferase
(β3GlcNAcT) [29–31], and a β1,3-galactosyltransferase (β3GalT) [32,33] nowadays enables an efficient
enzymatic synthesis approach towards linear HMOS. Elongation of lactose with N-acetyllactosamine
(Gal(β1-4)GlcNAc-, LacNAc type 2) or lacto-N-biose (Gal(β1-3)GlcNAc-, LacNAc type 1) represents a
basic motif of linear and branched HMOS. More precisely, the LacNAc units have to be β1-3-linked for
the correct biomimetic structure of linear HMOS while additional β1-6-linked LacNAc units form the
backbone of branched (iso-)HMOS [1].
Nevertheless, the Leloir-glycosyltransferases-mediated, isotopically labeled HMOS
synthesis depends on the availability of the isotope-labeled nucleotide sugars as
uridine-5´-diphospho-α-d-galactose (UDP-Gal) or uridine-5´-diphospho-α-d-N-acetylglucosamine
(UDP-GlcNAc). Synthesis approaches of isotope-labeled nucleotide sugars are not mentioned very
frequently in literature. An in vitro synthesis of 14C-enriched UDP-[14C]Gal was demonstrated already
50 years ago using an uridyltransferase [34]. Virgilio et al. incorporated 13C-labeled galactose by
the enzymatic synthesis in poly-LacNAc type II tetra- and hexaoses. The synthesis principle was
also demonstrated for the synthesis of non-labeled linear lacto-N-neo-type HMOS and therefore
postulated as a possible way towards isotopically labeled HMOS [35]. A chemoenzymatic strategy
for the synthesis of UDP-[2H]GlcNAc starting from the sugar-1-phosphate was performed using the
uridylyltransferases activity of the bifunctional Escherichia coli (E.coli) enzyme GlmU [36]. Recent
developments of cascades with salvage pathway enzymes and their use in novel synthesis strategies
can provide the nucleotide sugars UDP-Gal and UDP-GlcNAc in a much more efficient way [37–39].
Furthermore, recent studies impressively demonstrate the value of defined isotopically labeled OS for
in vivo research applications [40].
Here, we utilize a previously described strategy in a very efficient synthesis set-up for the production
of UDP-[15N]GlcNAc and UDP-[13C6]Gal on a 200 and a 400µmol scales. [39]. As previously demonstrated,
nucleotide sugars are readily accessible for Leloir-glycosyltransferases-mediated glycan synthesis without
further purification steps [32]. In this way, we demonstrate the synthesis of linear 13C6-labeled Lacto-N-type
and Lacto-N-neo-type HMOS up to octaoses as well as 13C6 and 15N-labeled lacto-N-neo-tetraose
([13C6/15N]LNnT), to the best of our knowledge, for the first time in a sequential enzymatic synthesis
cascade. Production in a 125 µmol scale of [13C6/15N]LNnT facilitates its application for absolute
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MALDI-TOF-MS-based quantification of tetraose in milk samples as a proof-of-concept exercise to show
the potential utility of tailored stable isotope-labeled HMOS for quantitative studies.
2. Results and Discussion
2.1. Nucleotide Sugar Synthesis
Synthesis of milk OS requires building blocks—monosaccharides. In order to be used in
oligosaccharide synthesis mediated by Leloir-glycosyltransferases, these monosaccharides need to
be activated first to a high-energy donor form—nucleotide sugars. Production of isotope-labeled
nucleotide sugars was carried out as described before, employing cascades of salvage pathway enzymes
in a repetitive batch approach (Supplementary Materials, Scheme S1) [39].
Briefly, within the nucleotide sugar-producing cascades, the monosaccharides (1 or 4) were
first phosphorylated by the respective ATP-dependent kinases (N-acetylhexosamine-1-kinase from
Bifidobacterium longum (NahK) or E.coli galactokinase (EcGalK)). The corresponding UDP-sugar
pyrophosphorylases (UDP-GlcNAc pyrophosphorylase (AGX1) or UDP-sugar pyrophosphorylase
from Hordeum vulgare (HvUSP)) catalyse the UTP-dependent UDP-sugar synthesis from the respective
sugar-1-phosphates (2 or 5), and an inorganic pyrophosphatase (PPiase) hydrolyses the inhibiting
by-product pyrophosphate (PPi) (Scheme 1). Regarding the repetitive batch synthesis strategy, a
centrifugal concentrator was utilized to carry out the enzymatic synthesis and for the subsequent
product separation of the respective batch. Each new cycle of the repetitive batch approach started
with the addition of fresh substrate to the enzymes, remaining in the concentrator (Supplementary
Materials, Scheme S1). From a commercial point of view, isotope-labeled monosaccharide substrates
are rather precious. With this in mind, the synthesis conditions for compounds 3 and 6 were carefully
adjusted to increase the product yield. By pre-tempering of all reaction solutions and elongation of
the reaction time to one hour, we were able to obtain full substrate conversion (Table 1). Product
concentrations were determined by capillary electrophoresis with UV detection (CE-UV) (data not
shown) and the product verification was carried out via electrospray ionization mass spectrometry
(ESI-MS) as previously reported (Table 1; Supplementary Materials, Figures MS1, and MS2) [32,37,39].
The non-labeled nucleotide sugars utilized in this study were available from our earlier work [39]
(Supplementary Materials, Figures MS3, and MS4). The synthesized compound 6 (UDP-[13C6]Gal)
contains isotopically enriched galactose with a stable 13C incorporated at each carbon position of the
hexose which causes the mentioned mass difference of 6 compared to the natural compound (UDP-Gal).
Accordingly, incorporation of the stable isotope 15N in GlcNAc causes a one-unit mass difference in
compound 3 when compared to the non-labeled UDP-GlcNAc.
Table 1. Analysis of the synthesized nucleotide sugars compounds 3 and 6 by capillary electrophoresis
with UV detection (CE-UV) and electrospray ionization mass spectrometry (ESI-MS).
Compound Amount [µmol] Average Yield [%] Calculated m/z [M − H]− Observed m/z [M − H]−
3
(UDP-[15N]GlcNAc) 200 100% 607.1
(a) 607.2
6 (UDP-[13C6]Gal) 400 100% 571.3 (a) 570.9
UDP-GlcNAc (a) 606.1 606.2
UDP-Gal (a) 565.3 (a) 564.9
(a) Provided from our previous study [39].
The direct salvage enzyme cascades utilized in this study are characterized in previous works by
great space-time yields and high stability under optimized reaction conditions [23,38,39]. Additionally,
their application into a repetitive batch approach maximizes the enzyme productivities and reduces,
therefore, enzyme preparation time and effort to the minimum (Supplementary Materials, Table S1).
As demonstrated in previous studies for the synthesis of a set of non-labeled nucleotide sugars,
this synthesis approach is highly reproducible and can be easily scaled up to a multi-gram scale without
extensive laboratory effort [39]. Due to a complete conversion, unreacted sugars and intermediates
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were not present, while nucleotides can be straightforwardly degraded, using an alkaline phosphate.
As previously demonstrated, obtained nucleotide sugar solutions are ready to use for a subsequent
Leloir-glycosyltransferases-mediated glycan synthesis [32].
Scheme 1. Repetitive batch synthesis for (A) isotope-labeled UDP-[15N]GlcNAc (3) by the
N-acetylhexosamine-1-kinase (NahK), UDP-GlcNAc pyrophosphorylase (AGX1), and an inorganic
pyrophosphatase (PPiase) and (B) isotope-enriched UDP-[13C6]Gal (6) by galactokinase (EcGalK),
the UDP-sugar pyrophosphorylase from Hordeum vulgare (HvUSP) and PPiase.
2.2. HMOS Synthesis
The synthesized nucleotide sugars were used without any further purification step in a sequential
synthesis of 13C6-labeled and non-labeled linear HMOS with type I or type II LacNAc extensions of
the lactose core as depicted in Scheme 2. The respective reaction progress was monitored by capillary
electrophoresis with laser-induced fluorescence detection (CE-LIF). Suitable internal standards for
migration time alignment allowed for product assignment including the challenging linkage isomers
(Supplementary Materials, Figures S1–S5).
Scheme 2. Sequential enzymatic synthesis of human milk oligosaccharides (HOMS). Compounds 10,
12, 14, 16, 18, 20, 22, and 24 contain 13C6-enriched galactoses in each LacNAc unit. Compounds 8, 9, 11,
13, 15, 17, 19, 21, and 23 were synthesized as unlabeled HMOS.
Product characterization and determination of relative conversion rates were carried out using more
sensitive, high-performance multiplexed capillary gel electrophoresis with laser-induced fluorescence
detection (xCGE-LIF). xCGE-LIF has proven as an ideal separation tool for oligosaccharide analysis,
enabling rapid separation and detection of isomeric compounds, even with small differences in the
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monosaccharide composition, positions, and linkages [16,41–46]. This technique can be employed
in a multi-capillary format (up to 96 capillaries), making the method high-throughput and thereby
appropriate for enzyme reaction monitoring and product identification [47]. The normalized migration
times of synthesized isotopically labeled HMOS were compared to the normalized migration times
of commercial native HMOS standards if available (Figure 1). Identification and annotation of
OS were carried out primarily based on our internal HMOS database (comparison of migration
times). Identification and annotation of synthesized HMOS by comparison of migration times with
in-house database entries (consisting of commercially available standards and previously annotated
structures) was feasible for all synthesized structures since a wide range of linear HMOS, even the
ones with minor structural differences, were extensively characterized and annotated previously [23].
Compositions of products were verified by LC-ESI-MS and MALDI-TOF-MS (Supplementary Materials,
Figures MS5–MS17 and MTS1–MTS7).
Figure 1. Multiplexed capillary gel electrophoresis with laser-induced fluorescence detection (xCGE-LIF)
analysis of the linear HMOS synthesis products: tetraoses (A), hexaoses (B), and octaoses (C). Upper
electropherograms show (i) 13C6 galactose-enriched compounds 10, 14, 18, 20, 22, and 24 and (ii)
centered native compounds 9, 13, 17, 19, 21, and 23. The bottom electropherograms display (iii)
the migration time matching with commercially available standards. Lacto-N-neo-type HMOS were
analyzed after 24 h reaction time, while the final reaction step for Lacto-N-type (terminal β3Gal)
compounds was carried out after 72 h. Symbolic representation of oligosaccharide structures is drawn
with GlycoWorkbench v.1.0.3353 by the guidelines of the Consortium for Functional Glycomics: blue
circle, glucose; blue square, N-acetylglucosamine; yellow circle, galactose [48,49].
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Formation of the synthesis intermediates (GlcNAc-terminated structures) was pushed to a
quantitative conversion respectively by the addition of fresh enzyme and elongation of the reaction
time up to 72 h if necessary (Supplementary Materials, Figure S1). With respect to the known
specificity, the production of Lacto-N-triose II (GlcNAc-β1,3-Gal-β1,4Glc) has to be considered critically.
The β3GlcNAcT is known for good conversion of longer poly-LacNAc type II motives [30,32] but also
for a bad acceptance of structures without N-acetyl group [23,50]. Nevertheless, we were able to reach
92.3% conversion of lactose within 48 h and nearly full conversion (99.7%) after 68 h reaction time as
exemplarily depicted in Figure S6 (Supplementary Materials). The N-acetyllactosamine type II core
(Galβ1-4GlcNAc) was synthesized by the β3GlcNAcT from Helicobacter pylori and the human β4GalT
which are already known for a good substrate conversion in poly-LacNAc syntheses [30].
Synthesis of Lacto-N-type HMOS (Galβ1-3GlcNAc) was carried out by the E.coli β3GalT (WbgO)
as described previously [32]. The acceptor’s structure differs from the known sugar structures
occurring in the E.coli O55:H7 O-antigen repeating unit [33]. Here, the substrate acceptance could
be one important reason why we were not able to push the enzymatic reaction to a quantitative
conversion (Figure 1B,C). We assumed further an enzymatic limitation, especially for longer structures,
which was also observed in the previously published sequential synthesis of poly-LacNAc type I [32].
Regarding the lacto-N-neo-type HMOS synthesis, we mainly achieved good conversions (Figure 1;
Supplementary Materials, Figures MTS1–MTS5). Surprisingly, we obtained only a yield of 73% within
the last sequential synthesis step for compound 18 ([13C6]lacto-N-neo-octaose). On the contrary, we
obtained nearly full conversion (99.5%) for the synthesis of compound 17 with nearly the same reaction
conditions (Figure 1; Supplementary Materials, Figure MTS6). Therefore, we assumed no enzymatic
or structural limitation in this synthesis step especially since no substrate length limitation for the
used human β4GalT is known from the previous studies [30,32,51]. Therefore, we rated the enzymatic
elongation toward longer HMOS as feasible, possibly after a clean-up which removes reaction residues
from earlier steps. Since the scope of this study focuses on a semi-sequential synthesis set-up without
purification steps and we were not aiming for even longer structures, we did not investigate this further.
The sequential synthesis of 13C6 and 15N-labeled lacto-N-neo-tetraose ([13C6/15N]LNnT) depicted
in Scheme 3 delivers an overall synthetic yield (lactose-based) of 91.6% (Supplementary Materials,
Figures S6 and MTS7 (purified compound 25)). Starting from the isotopically labeled monosaccharides
[13C6]Gal and [15N]GlcNAc, the incorporation yield was calculated to be 74.2% overall synthetic
steps. Hereby a slight excess of nucleotide sugars used for the transferases-mediated synthesis steps
to [13C6/15N]LNnT affects the incorporation yield. Nevertheless, we rated the introduced synthesis
strategy as a very efficient approach. In addition, we achieved the synthesis of [13C6/15N]LNnT in a
multi-µmol scale (106 µmol). For its application as an internal standard in the quantification of milk
OS, it was necessary to confirm that the compound was obtained in good quality, with no other milk
OS in the sample that could compromise the purity and consequently quantification accuracy. Purity
and identity of the isotopically enriched standard were confirmed by xCGE-LIF and MALDI-TOF-MS
(Supplementary Materials, Figure MTS7). We observed the desired compound only and no lactose or
triose after purification by an ultra-dialysis step. Additionally, to determine the number of OS, it was
necessary that the standard used is quantitative. Therefore, an aliquot of the synthesized and purified
[13C6/15N]LNnT isotope-standard solution was estimated by total organic carbon (TOC) analysis
(Supplementary Materials, Figure TOCS1, and Table TOCS1). Data obtained enabled us to apply the
compound as a quantitative standard for a proof-of-concept exercise showing the potential utility of
enzymatically synthesized standards for quantification of HMOS, even in a complex matrix like milk.
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Scheme 3. Sequential enzymatic synthesis cascade for 13C6 and 15N-labeled Lacto-N-neo-type tetraose
(compound 25). (A) Synthesis of Lacto-N-triose II using previously synthesized UDP-[15N]GlcNAc as
a substrate. (B) Synthesis of [13C6/15N]LNnT, [13C6]Gal(β1,4)[15N]GlcNAc(β1,3)Gal(β1,4)Glc using
previously synthesized UDP-[13C6]Gal.
2.3. Absolute Compound Quantification in Complex Samples by MS
There is an increasing amount of reports showing that biological functions of HMOS depend not
only on the specific structure of an HMOS but also on the quantity of the HMOS [52–56]. Therefore,
in order to better understand all the effects of HMOS on infant health and risk of diseases, it is important
to be able to quantify these compounds. Accurate, sensitive, fast, and straightforward methods that
can quantify these compounds even in complex matrixes ranging from body fluids to food formulas
will be essential for future studies.
Besides chromatography (e.g., high-performance liquid chromatography with UV or fluorescence
detection and high-pH anion-exchange chromatography with pulsed amperometric detection) [57–66]
and electrophoresis (e.g., CE-UV and CGE-LIF) [16,67–70], MS has emerged as one of the methods of
choice for the elucidation and characterization of milk OS from various sources because of its high
resolving power, specificity, and selectivity, which is the result of differentiation of compound based on
specific masses and from the fragmentation specific to linkage and monosaccharide sequence [15,71–74].
MALDI-MS has become a fast, simple, and convenient method for the analysis of even complex HMOS
mixtures [75–77]. However, studies on the analysis of HMOS using MALDI-MS have been mainly
qualitative as the absolute quantification is compromised by structure-dependent ionization efficiencies,
ion suppression in complex samples, fluctuations in instrument performance, and variability in matrix
crystallization. These sources of variability in MALDI-TOF-MS can be greatly diminished by the use of
stable isotope-labeled standards. Briefly, due to the introduced mass difference, there is no overlap in
the spectra between native and stable isotopes-labeled analytes. Both the analyte and its isotopic pair
have equal ionization efficiency so that, when spiked to the analyte-containing sample in a known
concentration, the isotope-labeled internal standard acts as a molecular balance. Given that the molar
ratio of the isotopologues is within the linear range of the so-called response factor, one can easily
compare their signal intensity or area under the curve (AUC) and deduce absolute quantities. Absolute
quantification by MS employing stable isotope-labeled internal standards has been a routine method
in metabolomics and proteomics and is recently introduced for quantification of another group of
complex OS—N-glycans [17,78–82]. In contrast, quantification of milk OS by MS has been hampered
largely by a lack of isotope-labeled HMOS standards. This study aimed to overcome this issue by an
enzymatic synthesis of isotope-labeled HMOS.
Molecules 2019, 24, 3482 8 of 21
As one example for the use of these enzymatically synthesized heavy isotope-labeled HMOS
standards, we applied [13C6/15N]LNnT for the MALDI-TOF-MS-based absolute quantification of
commercial LNnT spiked into homogenized bovine milk. In comparison to human milk, bovine
milk contains qualitatively and quantitatively fewer OS (25 identified of the 39 reported) [83,84].
Nevertheless, it was essential to prove that there was no detectable tetraose in commercial bovine milk
used as a matrix to be spiked with commercial and synthesized isotope-labeled LNnT. (Supplementary
Materials, Figure MTS8). The 7 Da mass increment of [13C6/15N]LNnT over the native compound
LNnT facilitated a clear separation of the isotopic profiles, which was a necessary prerequisite for
an accurate quantification (Supplementary Materials, Figure MTS9). To evaluate the response factor
and dynamic range of the MALDI-TOF-MS analysis, LNnT and [13C6/15N]LNnT were analyzed with
varying molarities (Figure 2A). The coefficient of determination (R2) of 0.999 confirms the linear
response for relative molarities of LNnT to [13C6/15N]LNnT from 0.1 to 10. Furthermore, the response
factor and dynamic range were investigated taking into account the complete sample preparation
workflow (Figure 2B). The linear regression (R2 = 0.998) for samples extracted from bovine milk is in
great accordance with the direct analysis of LNnT and [13C6/15N]LNnT. The data indicates no negative
effect of the sample preparation for absolute quantification.
Figure 2. Calibration plots for the response function of LNnT to [13C6/15N]LNnT by matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS). [13C6/15N]LNnT was mixed
commercial LNnT in H2O (A) and bovine H-milk (B), covering a broad spectrum of concentrations
(0.25 µM to 1.5 mM). The graph displays averaged replicates with error bars representing the standard
deviation (n > 3). LNnT and [13C6/15N]LNnT were purified from bovine H-milk (Weinstephan, 3.5%
fat) by porous graphitized carbon-solid-phase extraction (PGC-SPE).
In order to challenge the method in a more complex matrix, we used [13C6/15N]LNnT as an
internal standard for the quantification of tetraose in a human milk sample, collected 153 days
postpartum. As complexity and oligosaccharide content of human milk far exceeds the one from
bovine milk, with some reporting at least 1000 different OS in human milk [77], it was necessary to
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examine that there were no compounds interfering with the quantification. Therefore, OS extracted
from the human milk sample were analyzed without the addition of the isotope-labeled standard
(Figure 3A). The zoom into the m/z range from 726 to 746 (Figure 3A-ii) shows not only the expected
isotopic distribution of tetraose (monoisotopic peak indicated by an asterisk) [85] but also an otherwise
flat baseline. These findings approve the eligibility of [13C6/15N]LNnT as an internal standard
for MALDI-TOF-MS-based quantification of tetraose in human milk. In an analogous manner
to the aforementioned results, different quantities of human milk (0.25 to 3 µL) were diluted in
H2O and spiked with 1 µL [13C6/15N]LNnT (1 mM). A representative measurement is depicted in
Figures 3B-iii and 3B-iv, showing human milk-derived tetraose (m/z of 730.6 [M + Na]+) and the
enzymatically synthesized standard (m/z of 737.6 [M + Na]+) with a mass difference of 7 Da (based on
singly charged species). The early incorporation of the internal standard into the human milk sample
resulted in improved reproducibility and robustness of the quantification, due to the identical treatment
of target compound and standard. This advantageous feature was confirmed by the linear response
function (R2 = 0.9927) of tetraose and [13C6/15N]LNnT, extracted from human milk (Supplementary
Materials, Figure S7). Based on linear regression, a tetraose concentration of 1.33 mM was determined
for the human milk sample (153 days postpartum). The exemplarily shown utilization of 1 µL internal
standard (1 mM) enables the precise quantification of tetraose from human milk over a relative
concentration range of more than 1 order of magnitude (application of 0.25 to 3 µL human milk).
Therefore, the enzymatically tailored HMOS evade the need for time- and labor-intensive preliminary
experiments to find adequate standard concentrations for different sample sets.
Nevertheless, the applied MALDI-TOF-MS-based method has some drawbacks, like the inability
to distinguish the linkage isomers lacto-N-tetraose (LNT) and LNnT, both present in human milk [2,6].
While there are techniques like the analysis of post-source decay fragment ions and instruments such
as ion-mobility MS, which are facilitating additional resolution, these approaches demand not only
appropriate equipment but also certain expertise. However, the use of isotope-labeled standards while
incorporating a high-resolution separation step prior to MS should increase information gained and
improves the quantification process by separating various isomers that cannot be differentiated by
mass alone.
Results obtained by different groups analyzing concentrations of LNnT and LNT reported in
human milk vary considerably. Such variation may be attributed to the general biological variability
as well as to other biological parameters like gestational age, Lewis blood group, secretor status of the
mother, lactation period, or analytical methods [8,86]. All this variability makes it difficult to compare
the presented results with other studies. LNT and LNnT are naturally occurring tetrasaccharides
belonging to the group of non-fucosylated neutral HMOS. It was shown that they could protect against
important systemic infections of the newborn [9,87–89]. In addition, they act as natural prebiotics,
promoting the growth of beneficial gut microbiota (bifidobacteria and lactobacilli), thereby suppressing
the growth of undesirable bacteria [90–93]. LNnT is, besides 2´-fucosyllactose (2′-FL), the only
synthetically produced oligosaccharide approved by the European Food Safety Authority (EFSA) for
supplementation to infant formula [12]. For these reasons, a fast, accurate, and sensitive method that
can quantify these OS will be very useful for future studies.
Another reported approach which is taking advantage of the mass difference between the light and
heavy form of an oligosaccharide is based on the incorporation of stable isotopes into OS by reductive
amination [18,94,95]. One sample is reduced with sodium borohydride, and another is decreased with
sodium borodeuteride, and afterward, two samples are mixed in a 1:1 (v/v) ratio. The ratios of light and
heavy isotope-labeled OS are then used to compare the relative intensities between the two samples.
Limitation of this approach is that only the relative quantification is achieved and, due to overlapping
isotopic signals of unlabeled and labeled OS, analysis becomes more difficult. With the availability of
isotopically labeled HMOS standards, the MALDI-TOF-MS-based approach can position itself as a fast,
simple, sensitive, and precise tool for HMOS quantification, even in a complex sample.
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Figure 3. (A) MALDI-TOF mass spectrum of PGC-SPE extracted human milk in the m/z range from
300 to 2500 (i) and the magnified m/z range from 726 to 746 (ii). An asterisk indicates the signal
corresponding to tetraose (m/z = 730.6204 [M + Na]+). (B) MALDI-TOF mass spectrum from PGC-SPE
extracted human milk spiked with [13C6/15N]LNnT. An asterisk in the in the m/z range from 300 to
2500 (iii) indicates the signals corresponding to tetraose (m/z = 730.6204 [M + Na]+ and [13C6/15N]
LNnT (737.641 [M + Na]+). The two isotopologues are highlighted in the amplified m/z range from 726
to 746 (iv).
3. Materials and Methods
3.1. Recombinant Enzyme Preparation
Expression and subsequent purification of the recombinant transferases: the human
β1,4-galactosyltransferase-1 (β4GalT), the E.coli O55:H7 β1,3-galactosyltransferase (β3GalT), and a the
β1,3-N-acetylglucosaminyltransferases from Heliobacter pylori (β3GlcNAcT) were carried out as
described previously [23,27,29,30,32]. For the β3GalT and the β3GlcNAcT, a buffer exchange was
carried out by dialysis (10 kDa cut-off). The β3GalT dialysis buffer contained 100 mM NaH2PO4 at
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pH 7.5, 500 mM NaCl, and 5 mM DTT. The β3GlcNAcT dialysis buffer consisted of 20 mM Tris-HCl
at pH 7.4, 200 mM NaCl, 1 mM EDTA and 1 mM DTT. The purified enzymes were stored at 4 ◦C.
Heterologous kinases and pyrophosphorylases expression, as well as purification, were done as
published before [37–39]. EcGalK, HvUSP, NahK, and the human AGX1 were subsequently diafiltrated
and concentrated in a 30 kDa centrifugal concentrator (Vivaspin®20) from Sartorius (Göttingen).
Therefore, a 50 mM Tris/HCl buffer (pH 7.5) was used. EcGalK and AGX1 were stored at −20 ◦C, and
β4GalT, β3GalT, β3GlcNAcT, NahK, and HvUSP were stored at 4◦C after the buffer exchange.
3.2. Enzyme Activity Assay
Kinases and pyrophosphorylases activity tests were carried out in a 96-well plate format
on a multiplexed capillary electrophoresis system with UV detection (MP-CE (UV)) as described
before [37–39]. Briefly, the reactions were carried out in a volume of 300 µL and at 37 ◦C. The reaction
mixture for NahK contained 1 U pyrophosphatase from Saccharomyces cerevisiae (Sigma-Aldrich (Roche)),
2 mM GlcNAc, 2 mM ATP, and 2 mM MgCl2 and was buffered by 50 mM Tris(HCl) at pH 8.0. The
AGX1 reaction mixture was also buffered by a Tris(HCl) system (pH 8.0) and supplemented with
2 mM GlcNAc-1-P, 2 mM MgCl2, 2 mM UTP, and 1 U pyrophosphatase. For the EcGalK reaction
mixture, 2 mM Gal, 2 mM MgCl2, 2 mM ATP, and 1 U pyrophosphatase were buffered at pH 7.5 by
50 mM Tris(HCl), while the HvUSP mixture contained 1 U pyrophosphatase, 2mM Gal-1-P, 2 mM
MgCl2, and 2 mM UTP in a 50 mM Tris(HCl) buffer system (pH 7.5). The reactions were stopped at
different time points by the addition of a termination solution, containing sodium dodecyl sulfate
(SDS), to a final concentration of 7 mM to denature the enzymes immediately. Internal normalization
standards, 4-aminobenzoic acid (PABA) and 4-aminophthalic acid (PAPA), were added to the sample
solution together with the termination solution to a final concentration of 1 mM, respectively. The peak
areas were normalized to PABA, and the concentrations were determined via calibration curves as
formerly published [37–39]. Kinases activities were determined by increasing ADP concentrations.
While the pyrophosphorylases activities were determined by the UDP-sugar increase over time.
The quantification of these UV-active compounds was carried out as formerly described by Wahl et
al. at a wavelength of 254 nm [37]. More precisely, a calibration curve was recorded for the peak
area of commercial standards normalized to the peak area of 1 mM para-amino benzoic acid (PABA)
plotted against the varying standard concentration. Analytes concentrations were deduced from the
linear slope area, calculated with the obtained normalized peak area. Therefore, one µmol substrate
conversion per minute was defined as 1 U (enzyme unit).
Transferases activity assays were carried out and analyzed on CE-LIF as described previously [23].
Shortly, all reaction mixtures were incubated at 30 ◦C and contained 6.5 mM MnCl2, 6.5 mM MgCl2
as well as 6 U alkaline phosphatase (AP) (ThermoFischer) buffered by 100 mM Tris(HCl) at pH 7.5.
Each 5 mM of the respective acceptor substrate, 6.5 mM of the respective nucleotide sugar, and 10 µg
purified enzyme were supplemented to start the reactions. More precisely, lactose and UDP-GlcNAc
were used for the β3GlcNAcT assay, and Lacto-N-triaose and UDP-Gal were used for the β4GalT and
β3GalT assays. The enzyme reactions were stopped by heating up small samples (6 µL, 95 ◦C for
5 min) on different time points. After centrifugation, the supernatant (2 µL) was used for fluorescent
labeling (8-aminopyrene-1,3,6-trisulfonic acid (APTS)), post-derivatization hydrophilic interaction
chromatography-solid phase extraction (HILIC-SPE) sample clean-up and analysis via CE-LIF as
described in the Method section and previous studies [23,43]. The volumetric activity (U/mL) was
calculated from the linear slope area.
3.3. HMOS Analysis via CE-LIF and xCGE-LIF
CE-LIF was mainly used to determine the transferases activity, as described above, and follow the
HMOS synthesis reaction. APTS labeling, HILIC-SPE clean-up, and CE-LIF measurement were carried
out as described before [23,43]. Additionally, commercial maltose, cellooctaoses, and maltononaoses
were spiked as internal migration time normalization standards. High-resolution and -sensitivity
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xCGE-LIF analytics were used for a structure verification based on a migration time matching to the
in-house database and commercially available standards [39]. Sample preparation including APTS
labeling, HILIC-SPE, and further xCGE-LIF measurement and analysis was carried out as detailed
described before [42,43].
3.4. Nucleotide Sugar Synthesis
UDP-[13C6]galalactose and UDP-N-acetyl-[15N]glucosamine were produced as published before
in a repetitive batch mode using a centrifugal concentrator device (Vivaspin®) as a reactor and
separation device [39]. For the synthesis, commercially available isotopically labeled monosaccharides
(Sigma/Campo and Omicron Biochemicals) were used. To receive an optimal conversion, all reaction
solutions were pre-tempered, and the synthesis reaction time was elongated to each one h in total.
The concentration was determined as described before by MP-CE (UV) analysis [37–39]. Briefly,
the product concentrations were determined by the peak area normalized to the internal standard
PABA and calculated using a calibration curve of the corresponding commercial non-isotope-labeled
nucleotide sugars.
3.5. Sequential 13C6 and Native HMOS Synthesis
For the sequential synthesis of compound 8, the initial reaction mixture was buffered by 100 mM
Tris/HCl (pH 7.5). The mixture contains further 25 mM KCl, 1 mM MgCl2, 1 mM MnCl2, 1 mM lactose
(compound 7), 1 mM in-house produced UDP-GlcNAc, and 20 mU/mL AP. β3GlcNAcT (50 mU/mL)
was added to start the reaction in a total volume of 2 mL, respectively. The reaction was incubated at 30
◦C for at least 24 h. The product formation was monitored by CE-LIF as described in the corresponding
section. If necessary, the reaction time was elongated to 72 h and fresh enzyme and nucleotide
sugar were supplemented after 24 h. Removal of the enzymes between the sequential steps was
carried out by an ultra-filtration step using a centrifugal concentrator as recommended by the supplier
(Vivaspin®500 from Sartorius, 10 kDa). Ongoing sequential product elongation with constant buffer
and compound compositions (mentioned above) was started by the addition of AP, the respective
transferase (250 mU/mL β4GalT, 150 mU/mL, β3GalT mU/mL, or 50 mU/mL β3GlcNAcT) and the
respective in-house produced nucleotide sugar. Defined lengths of HMOS (target compounds 10, 14,
18, 20, 22, 24 and 9, 13, 17, 19, 21, 23) were synthesized by alternating addition and removal of the
transferases β3GlcNAcT, β4GalT, or β3GalT and the respective in-house synthesized nucleotide sugar
starting from lactose. The progress of each enzymatic elongation step was monitored by CE-LIF and
additional structural characterization was performed by xCGE-LIF, LC-ESI-MS, and MALDI-TOF-MS,
as described elsewhere in this paper.
3.6. Sequential Synthesis of 13C6 and 15N-Labeled Lacto-N-Neo-Tetraose
Synthesis of 13C6 and 15N-labeled LNnT (compound 25, [13C6]Gal-β1,4-[15N]GlcNAc-
β-1,3-Gal-β-1,4-Glc) was carried out on a 125µmol scale. The reaction contained 6.25 mM MgCl2, 25 mM
KCl, 5.5 mM pre-synthesized UDP-[15N]GlcNAc, 5 mM lactose, and 1 mM DTT in a Tris/HCl buffer
system (pH 7.5). Addition of 100 mU/mL β3GlcNAcT and 20 mU/mL AP started the reaction. After 48 h
at 30 ◦C, the intermediate formation was monitored by CE-LIF as described in the corresponding
section, which took additional 20 h (labeling, clean-up, and measurement). Afterward, the reaction
was stopped by heat inactivation of the involved enzymes for 5 minutes at 95 ◦C. Further elongation
was carried out by the addition of 6.25 mM MgCl2, 250 mU/mL β4GalT, 20 mU/mL AP, and 5.5 mM
pre-synthesized UDP-[13C6]Gal. The reaction was stopped by a heat-inactivation step (5 min/95 ◦C)
after an additional 48 h incubation at 30◦C and the final product formation was analyzed by CE-LIF.
The [13C6/15N]LNnT was pre-treated for further experiments by ultra-dialysis. Briefly, enzymes
were removed after heat precipitation by centrifugation. Low-molecular-synthesis compounds were
removed by at least 3 times low-cut-off (100–500 Da, FloatALyser®G2) dialysis against ultrapure water
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overnight monitored by a conductivity meter. The samples were dried in a vacuum concentrator at 60
◦C overnight and resolved in ultrapure MilliQ water.
3.7. TOC Analysis of the Purified [13C6/15N]Lacto-N-Neo-Tetraose
The organic carbon content of the samples was determined by a Sievers M9 TOC Analyzer (GE
Analytical Instruments, Manchester, United Kingdom) by measuring the difference between the total
carbon (TC) and the total inorganic carbon (TIC). TC of the sample was wet-chemical oxidized with
UV radiation forming CO2 which passed a CO2 permeable membrane for detection by conductometry.
TIC was reacted to CO2 using phosphoric acid and passed the same CO2-permeable membrane for
detection by conductometry. The TOC value was given by the difference between these two values:
TOC = TC – TIC. The measurement was conducted at a sample flow of 0.5 mL/min while adding
1 µL/min phosphoric acid (6 M) and 2.8 µL/min ammonium persulfate solution (15% w/w) for a working
range up to 50 ppm TIC and 10 ppm TOC. The detection range was specified by the manufacturer
from 0.03 ppb to 50 ppm with a precision of ±2%. The initial calibration was done with potassium
hydrogen phthalate (Merck KGaA, Darmstadt, Germany, 1.09017.0100) and was linear in a range
from carbon-free samples up to 10 ppm organic carbon. Of the samples, 1 mg was weighed with a
Mettler AT 261 Delta range balance (±0.02 mg accuracy) and dissolved in 10 mL ultrapure water. These
solutions were diluted 10 and 20 times with ultrapure water and measured against the same ultrapure
water as blank. For validation of the method, the carbon content of α-Lactose Monohydrate (Merck
KGaA, Darmstadt, Germany) was calculated by measuring the corresponding TOC and dividing it
by the initial sample weight. The agreement between the experimental value (39.67% w/w) and the
theoretical value (39.97% w/w) shows the high accuracy of the method.
3.8. MS-Based Analysis
All experiments, including sample preparation steps for MS measurements, were carried out
using LC-MS-grade water and chemicals if not stated otherwise. Qualitative characterization of
the synthesized HMOS standards was carried out as described previously [23]. All enzymatically
synthesized HMOS samples were prepared for MS analysis by ultra-dialysis as detailed described
above for the [13C6/15N]LNnT pre-treatment.
3.9. Nucleotide Sugar and HMOS Analysis via ESI-MS
Mass verification of the nucleotide sugars in pre-treated samples was carried out as described
previously [39]. Briefly, the remaining reaction residuals (nucleoside phosphates) were removed
from the samples by an AP digest overnight at room temperature. Afterward, the enzymes were
removed by an ultra-flirtation step using a centrifugal concentrator as recommended by the supplier
(Vivaspin®500 from Sartorius, 10 kDa). Flow-through samples of prepared compounds 1–4 were partly
supplemented with 0.1–0.5 µL ammonium hydroxide. Their subsequent analysis was performed on a
Dionex HPLC system equipped with a Multospher 120 RP 18 HP-3µ HPLC column (60 mm × 2 mm)
from CS-Chromatographie Service GmbH, Langerwehe. Therefore, an MS-grade ACN/water (50:50,
v/v) mixture was used as a mobile phase with a flow rate of 0.2 mL min−1. Mass data were collected
with a connected ESI-MS detector (Finnigan Surveyor MSQ Plus from Thermo Scientific) in a negative
mode. The temperature was set to 400 ◦C, the needle voltage was set to −4 kV, and the cone voltage
was set to 100 V.
The samples were supplemented with small amounts (0.1–0.5 µL) of ammonium hydroxide.
Afterward, HMOS mass was analyzed using an LC-ESI-MS system. Therefore, a Dionex system was
equipped with a polymer-based HILIC column (Shodex Asahipak NH2-50 4E (4.6 × 250 millimeter
(mm))). As a mobile phase, an ACN:water gradient from 70% to 50% ACN over 15 minutes followed
by an additional 5 minutes with an isocratic flow at 50% ACN (1 mL/min) was used. Mass data
were collected using the conditions and the connected ESI-MS detector mentioned above for the
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nucleotide sugar analysis. All experiments for MS analysis were carried out with ultrapure water and
LC-MS-grade ACN.
3.10. Extraction of OS from Human Milk
The human milk sample was collected 153 days postpartum using a manual milk pump and
immediately stored at −20 ◦C. OS were isolated from human and bovine milk-based on a modified
version of a previously reported workflow [75]. Therefore, 0.25 to 3 µL of human milk was diluted to
49 µL with H2O and spiked with 1 µL [13C6/15N]LNnT (1 mM). Bovine milk (10 µL 3.5% fat H-milk
from Weihenstephan diluted to a final volume of 100 µL) was spiked with 1 µL [13C6/15N]LNnT (1 mM)
and 0.1 to 10 µL commercial LNnT (1 mM) (Elicityl, Crolles, France). All samples were centrifuged at
14,000× g and at room temperature for 20 min using a Heraeus Fresco 17 microcentrifuge (Thermo
Scientific, Bellefonte PA, USA). Subsequently, 60% of the aqueous phase was subjected to solid-phase
extraction (SPE). For each sample, approximately 2 mg porous graphitic carbon (PGC) from prepacked
25 mg cartridges (Thermo Scientific, Bellefonte PA, USA) were loaded onto Pierce C18 100 µL tips
(Thermo Scientific, Bellefonte PA, USA), placed in a 96-well PCR rack. To pass the liquid through the
stationary phase, the rack was placed on a 96-deep well storage plate and centrifuged at 500× g and at
room temperature for 1 min using a Heraeus Multifuge X1R (Thermo Scientific, Bellefonte PA, USA).
Equilibration of the stationary phase was achieved in two cycles of sequential application of 100
µL 40% (v/v) ACNaq and 100 µL 20% (v/v) ACNaq (both 0.1% (v/v) TFAaq), followed by 100 µL 0.1% (v/v)
TFAaq five times. After the application of approximately 60 µl sample, the PGC material was washed
five times with 100 µL 0.1% (v/v) TFAaq. Following elution in 70 µL 40% (v/v) ACNaq containing 0.1%
(v/v) TFAaq three times, all samples were dried for MALDI-TOF-MS analysis using a FRVC 2-33 CDplus
rotational vacuum evaporator (Martin Christ, Osterode am Harz, Germany) and resolubilized in 10 µL
H2O (extraction from human milk) or 20 µL H2O (extraction from bovine milk).
3.11. MALDI-TOF-MS Analysis and Absolute Quantification of HMOS
All MALDI-TOF mass spectra were acquired on an ultrafleXtreme MALDI-TOF/TOF-MS (Bruker
Daltonics, Bremen, Germany) in reflectron positive ion mode. For each spectrum, 15,000 laser shots
(50 shots per raster point in random walk) from a Smartbeam-II laser were averaged using a 120 ns
delayed extraction time and a 25 kV accelerating voltage. For external calibration of the m/z range
from 200 to 2500, a peptide standard mixture (Bruker Daltonics) and a dextran hydrolysate were used.
Analyte ionization was facilitated by freshly prepared super-dihydroxybenzoic acid (S-DHB) (≥99.0%,
Sigma-Aldrich, Steinheim, Germany) matrix (10 mg/mL) in 30% (v/v) ACNaq, 0.1% (v/v) TFAaq, and
4 mM NaCl. Therefore, 0.5 µL matrix solution was spotted onto an MTP AnchorChip 800/384 TF
MALDI target (Bruker Daltonics) and immediately dried in a vacuum evaporator, followed by 0.5 µL
sample spotted onto the matrix layer in an analogous manner.
All spectra were processed with flexAnalysis version 3.3 Build 80 (Bruker Daltonics), using the
top-hat filter for baseline subtraction and a centroid algorithm for peak detection with 0.5 m/z peak
width and a signal-to-noise ratio (SNR) threshold of 6. Processed spectra were exported in text format
and transferred to OriginLab 2019 and Microsoft Excel for data evaluation. To determine the methods
dynamic range and verify the direct proportionality of monoisotopic peak intensities from LNnT
(m/z 730.6204 [M + Na]+) and [13C6/15N]LNnT (m/z 737.641 [M + Na]+), three calibration curves were
prepared (one for each of the PGC-extracted samples (human and bovine milk) and one from a dilution
series of synthesized [13C6/15N]LNnT with the commercial LNnT standard.
4. Conclusions
To further deepen our understanding of the functions of milk OS, it is essential to first increase
our knowledge not only on the variety and complexity of these molecules in human milk but also
on their quantities. The quantification of these structurally complex and diverse but still similar
compounds is often limited by the small number of commercially available standards. Therefore,
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we strived to establish an approach to the enzymatic synthesis of stable isotope-labeled HMOS that
can be employed as internal standards for quantitative analysis. We provided a straightforward
synthesis strategy to isotopically labeled nucleotide sugars with high yields regarding the valuable
monosaccharide substrates. Further, we introduced a flexible sequential synthesis approach to efficient
tailoring of stable isotope [13C6]-labeled linear HMOS structures by the use of Leloir-glycosyltransferases.
We demonstrated synthetic capabilities as well as the potential and limitations of the introduced strategy
for selected HMOS up to octaoses. We further presented for the first time the enzymatic synthesis
of 15N-enriched UDP-[15N]GlcNAc and its precise incorporation in a [13C6/15N]Lacto-N-neo-tetraose
in a 106 µmol scale with an overall percentage yield (lactose-based) of 91.6%. Analysis of tetraose in
complex milk mixtures was thought as a proof-of-concept exercise to show that MALDI-TOF-MS-based
profiling method, when combined with well-defined 13C standards, can become a rapid, robust,
and sensitive method for absolute quantification of milk OS.
In conclusion, the presented synthesis approach enables increased access to an even broader set
of enzymatically tailored isotope-labeled HMOS than here described. Neutral HMOS (with type I
and II extensions) represent basic structural motifs of many known HMOS which are accessible for
further modifications, e.g., fucosylation or sialylation. Additionally, the sequential set-up combined
with a purification step allows for precise incorporation of an isotopic sugar unit on a freely selectable
position according to the respective demand. Tailored isotopically labeled HMOS could not only enable
fast and straightforward quantitative MALDI-TOF-MS-based analysis, but even allow quantifying
challenging linkage isomers of neutral HMOS when separation precedes detection by MS. The use of
stable isotope-labeled HMOS standards may help to gain more information about the concentrations
of OS in human milk or any other biofluid such as feces and urine, a crucial step towards a deeper
understanding of HMOS structure-function relations and implementation to infant nutrition.
Supplementary Materials: Additional CE-LIF electropherograms, as well as mass spectrograms, can be found in
Supplementary Materials. Figures S1–S6 exemplarily depict the sequential synthesis progress and separation
of challenging linkage isomers including the used internal migration time standards. Figures MS1–MS17 show
ESI-MS mass spectrums of the synthesized products including nucleotide sugars and HMOS. Figures MTS1–MTS6
show MALDI-TOF-MS mass spectrums of the synthesized HMOS. Figure MTS7 shows xCGE-LIF analysis and
MALDI-TOF-MS of the purified [13C6/15N]LNnT. Figure MTS7 shows the MALDI-TOF-MS mass spectrums of the
complex sample matrix—bovine milk—before and after spiking of model analytes and the isotopic [13C6/15N]LNnT
reference standard. Figure S7 shows the calibration plot for the response function to varying molar ratios of
tetraose to [13C6/15N]LNnT in human milk.
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